+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer



Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer



International Journal of Radiation Oncology, Biology, Physics 80(4): 1015-1022



To minimize toxicity while maintaining tumor coverage with stereotactic body radiation therapy (SBRT) for centrally or superiorly located stage I non-small-cell lung cancer (NSCLC), we investigated passive-scattering proton therapy (PSPT) and intensity-modulated proton therapy (IMPT). Fifteen patients with centrally or superiorly located (within 2 cm of critical structures) stage I NSCLC were treated clinically with three-dimensional photon SBRT (50 Gy in 4 fractions). The photon SBRT plan was compared with the PSPT and IMPT plans. The maximum tolerated dose (MTD) was defined as the dose that exceeded the dose--volume constraints in the critical structures. Only 6 photon plans satisfied the >95% planning target volume (PTV) coverage and MTD constraints, compared to 12 PSPT plans (p = 0.009) and 14 IMPT plans (p = 0.001). Compared with the photon SBRT plans, the PSPT and IMPT plans significantly reduced the mean total lung dose from 5.4 Gy to 3.5 Gy (p < 0.001) and 2.8 Gy (p < 0.001) and reduced the total lung volume receiving 5 Gy, 10 Gy, and 20 Gy (p < 0.001). When the PTV was within 2 cm of the critical structures, the PSPT and IMPT plans significantly reduced the mean maximal dose to the aorta, brachial plexus, heart, pulmonary vessels, and spinal cord. For centrally or superiorly located stage I NSCLC, proton therapy, particularly IMPT, delivered ablative doses to the target volume and significantly reduced doses to the surrounding normal tissues compared with photon SBRT.

(PDF emailed within 0-6 h: $19.90)

Accession: 055260495

Download citation: RISBibTeXText

PMID: 20615629

DOI: 10.1016/j.ijrobp.2010.03.012


Related references

Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer: in regards to Register et al. Int J Radiat Oncol Biol Phys 2011;80:1015-1022. International Journal of Radiation Oncology, Biology, Physics 82(1): 492; Author Reply 492, 2012

Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. International Journal of Radiation Oncology, Biology, Physics 72(4): 967-971, 2008

Phase I study of stereotactic body radiation therapy for centrally located stage IA non-small cell lung cancer (JROSG10-1). International Journal of Clinical Oncology 22(5): 849-856, 2017

Feasibility of helical tomotherapy in stereotactic body radiation therapy for centrally located early stage non‒small-cell lung cancer or lung metastases. International Journal of Radiation Oncology, Biology, Physics 81(3): 856-862, 2011

Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a "no fly zone". International Journal of Radiation Oncology, Biology, Physics 88(5): 1120-1128, 2014

Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics 101(3): 558-563, 2018

Stereotactic Body Radiation Therapy (SBRT) For Centrally Located Primary and Recurrent Non-Small Cell Lung Cancer: Analysis of Toxicity and Local Control. International Journal of Radiation Oncology*biology*physics 93(3): E418-E419, 2015

Stereotactic body radiotherapy for centrally located stage I non-small cell lung cancer. Translational Lung Cancer Research 8(1): 58-69, 2019

The potential role of respiratory motion management and image guidance in the reduction of severe toxicities following stereotactic ablative radiation therapy for patients with centrally located early stage non-small cell lung cancer or lung metastases. Frontiers in Oncology 4: 151, 2014

Primary Study Endpoint Analysis for NRG Oncology/RTOG 0813 Trial of Stereotactic Body Radiation Therapy (SBRT) for Centrally Located Non-Small Cell Lung Cancer (NSCLC). International Journal of Radiation Oncology*biology*physics 94(1): 5-6, 2016

Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry. Radiation Oncology 10: 113, 2016

Stereotactic ablative radiation therapy for centrally located recurrences of non-small cell lung cancer: in regard to Chang et al. International Journal of Radiation Oncology, Biology, Physics 89(5): 1141-1142, 2014

Clinical Comparison of Proton Beam Therapy and Stereotactic Body Radiation Therapy for Medically Inoperable Stage I Non-small Cell Lung Cancer. International Journal of Radiation Oncology*biology*physics 84(3): S573-S574, 2012

No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early- stage peripheral non-small cell lung cancer: an analysis of RTOG 0236. International Journal of Radiation Oncology, Biology, Physics 88(5): 1092-1099, 2014

Stereotactic Body Radiotherapy for Centrally Located Non-small Cell Lung Cancer. Zhongguo Fei Ai Za Zhi 21(5): 413-418, 2018